Atlas Trials

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Clinical trial NCT02545868 · COMPLETED

Trial details

NCT number
NCT02545868
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing-Remitting
Start date
2015-10-27
Primary completion
2017-02-14
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.